Published Medical Literature

Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis

AR-V7 Assays and Treatment Outcomes in Castration-Resistant Prostate Cancer

Combining Approved Treatments in Metastatic Castration-Resistant Prostate Cancer

Viral Vector–Based Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Duration of ADT With Radiation After Prostatectomy Depends on Risk Factors

Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer

ARAMIS Trial: Darolutamide in Nonmetastatic Prostate Cancer

Risk of Dementia From Androgen-Deprivation Therapy for Prostate Cancer

LATITUDE Trial: Survival Benefit With Combination Therapy for Prostate Cancer

Lipid-Lowering Medication and Risk of Prostate Cancer

Active Surveillance vs. Radical Treatment of Prostate Cancer

Impact of Race on Survival in Metastatic Castration-Resistant Prostate Cancer

Androgen-Deprivation Therapy for Prostate Cancer: Managing Cardiovascular Risks

Health-Related Quality of Life in Men With Advanced Versus Localized Prostate Cancer

Computer-Simulated Study Suggests Enlarged Prostate May Actually Hinder Tumor Growth

Is Time to Biochemical Failure a Surrogate Endpoint in Locally Advanced Prostate Cancer?

Duration of Androgen Suppression and Zoledronic Acid in Locally Advanced Prostate Cancer

Does Apalutamide Negatively Impact Quality of Life in Nonmetastatic CRPC?

AUA Guideline Amendment for Castration-Resistant Prostate Cancer

Closer Look at Types of Prostatectomy and Quality of Life

Does Androgen-Deprivation Therapy Increase Risk of Heart Failure in Men With Prostate Cancer?

Can Tyrosine Kinase Inhibitors for CML Affect PSA Titers Unrelated to Prostatic Disease?

Assessing Combination of Osteoprotective Agents and Anticancer Drugs in Prostate Cancer

Early Research on Birabresib in Prostate Cancer and Other Solid Tumors

Noninvasive Diagnosis of Prostate Cancer Using Novel Imaging Technique

Long-Term Results With Hormonal Therapy Plus Radiotherapy in Prostate Cancer

Active Surveillance for Prostate Cancer: Are Patients Being Lost to Follow-up?

PSA Screening for Prostate Cancer: Does It Really Reduce Disease-Specific Mortality?

Coffee Consumption and Disease-Free Progression in Patients With Localized Prostate Cancer

Are Researchers Closer to Diagnosing Aggressive Prostate Cancer at an Early Stage?

Rebiopsy for Prostate Cancer: Can Some Men With Negative MRI Avoid It?

Does Enzalutamide Affect Metastasis-Free Survival in Men With Aggressive Prostate Cancer?

Can Hypofractionated Radiotherapy Improve Prostate Cancer Control?

Low Free Testosterone Concentration May Equal Low Prostate Cancer Risk

Survival Impact of Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Does Surgical Technique Affect Outcomes in Patients With Prostate Cancer?

New Prognostic Imaging Biomarker in Metastatic Prostate Cancer

Report Sheds Light on Trends in Prostate Cancer

Pharmacoeconomic Implications of Low-Dose Abiraterone in Castration-Resistant Prostate Cancer

Predictors of Urinary Function After Prostatectomy

Updated USPSTF Screening Guidelines for Prostate Cancer

Timing of Catheter Removal After Robot-Assisted Radical Prostatectomy

Clinical Associations of Luminal and Basal Subtyping in Prostate Cancer

ASCO Clinical Practice Guidelines for Metastatic Noncastrate Prostate Cancer

Robot-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer

Dose-Escalated Radiation Therapy for Intermediate-Risk Prostate Cancer

After Disease Progression on Enzalutamide, Can Bipolar Androgen Therapy Make a Difference in Prostate Cancer?

SPARTAN Trial: Apalutamide in Nonmetastatic Prostate Cancer

Radiotherapy Versus Surgery for High-Risk Localized Prostate Cancer

Health-Related Quality of Life After Radical Prostatectomy